Please assess the completion status of the following clinical trial:

Trial Title: Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. SARS-CoV-2 positive~2. Age \>17 years and \< 80 years~3. P/F \< 250 mmHg~4. Bilateral pneumonia (infiltrates/interstitial)~5. CRP \>10mg/dL (or \>100mg/L)~6. Alternatively to 4-5-6 criteria a diagnosis of ARDS according to the Berlin definition (Ranieri M, et al. JAMA 2012)~Exclusion Criteria:~* Heart failure as predominant cause of acute respiratory failure~* Decompensated liver cirrhosis~* Cancer~* Organ transplantation~* HIV+~* dialysis~* long-term oxygen therapy, home mechanical ventilation~* Idiopathic pulmonary fibrosis~* Progressive neuromuscular disorders (e.g. Duchenne, Pompe, ALS)~* Dementia or decompensated psychiatric diseases~* immunosuppressive treatments~* Chronic use of corticosteroids~* Use of Tocilizumab~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Exposed to Methylprednisolone (Type: None): Consecutive SARS-CoV-2 positive patients with severe acute respiratory syndrome treated with methylprednisolone (MP) at low prolonged dose, fulfilling inclusion and exclusion criteria.
- Non-exposed to Methylprednisolone (Type: None): Concurrent patients fulfilling the same inclusion and exclusion criteria, never treated with steroids.

Based on this trial design, predict the completion outcome and termination type (if applicable).